Early experiments involved the use of a commercially available cationic liposomal reagent, LipofectamineTM 2000, to demonstrate the therapeutic value of siRNA-mediated c-myc inhibition in human colon cancer [55]. The gene discussed is MYC; the disease is colonic neoplasm.